Rajesh Malik - Jan 3, 2022 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Chief Medical Officer
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Jan 3, 2022
Transactions value $
-$15,334
Form type
4
Date filed
1/5/2022, 07:24 PM
Previous filing
Jul 8, 2021
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Award $0 +12K +22.51% $0.00 65.3K Jan 3, 2022 Direct F1, F2, F3
transaction GTHX Common Stock Sale -$15.3K -1.45K -2.21% $10.61* 63.9K Jan 5, 2022 Direct F4, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to buy) Award $0 +53K $0.00 53K Jan 3, 2022 Common Stock 53K $10.69 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2023 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Each RSU represents a contingent right to receive one share of Issuer common stock.
F3 Represents (i) 42,300 shares of common stock; (ii) 11,000 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022.
F4 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5 The price represents the weighted average price with a low of $10.45 and a high of $10.76. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Represents (i) 43,605 shares of common stock; (ii) 8,250 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022.
F7 The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.